Amylyx Pharmaceuticals Inc

Financials

Visión general Informes Estadísticas Dividendos

Activos totales 391.45 M517.45 M193.63 M332.64 M Total de pasivos 50.85 M84.02 M28.87 M27.39 M Capital total 340.61 M433.43 M164.76 M305.26 M Total de pasivos y patrimonio neto 391.45 M517.45 M193.63 M332.64 M Deuda total ———— Deuda neta ————

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

AMLX

Financials

Amylyx Pharmaceuticals Inc

Noticias

H.C. Wainwright reitera calificación de Amylyx por avance en ensayo

H.C. Wainwright eleva el precio objetivo de Amylyx a 34 dólares

H.C. Wainwright eleva precio objetivo de Amylyx a $34 por confianza en ensayo

H.C. Wainwright raises Amylyx stock price target to $34 on trial confidence

Amylyx Pharmaceuticals en TD Cowen: Perspectivas sobre Avexitide

Las acciones de Amylyx caen más del 3% por incertidumbre del ensayo pese a superar estimaciones

Acciones de Amylyx caen más de 3% por incertidumbre en ensayo pese a ganancias

Amylyx shares fall over 3% on trial uncertainty despite earnings beat

Stifel inicia cobertura de Amylyx con recomendación de compra

Stifel inicia cobertura de Amylyx con compra por potencial del fármaco

Stifel initiates Amylyx stock with buy rating on drug potential

Amylyx presentará resultados mientras ensayo de avexitide se acerca al final